COMMUNIQUÉS West-GlobeNewswire

Fairhaven Health Highlights Science-Driven Solutions for Women During Menopause Awareness Month
21/10/2025
MIDDLETOWN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- October marks Menopause Awareness Month, a time to focus on the physical and emotional changes that affect more than 1 million American women each year. Fairhaven [...]
Quercis Pharma and The Galien Foundation to Spotlight Sickle Cell Disease at the 2025 Patient Summit
21/10/2025
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Quercis Pharma is proud to sponsor Panel 6 — “The Forgotten Patients: A Focus on Sickle Cell Disease” at The Galien Foundation’s 2025 Patient Summit, taking place on Thursday [...]
beyond|AESTHETICS Owner Leslie Petersen, NP, Accepted into Elite Dr. Mauricio de Maio MD Codes™ Fellowship Program
21/10/2025
Camarillo, CA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- beyond|AESTHETICS is proud to announce that its owner, Leslie Petersen, NP , has been selected as one of only 15 individuals nationally for the highly coveted Dr. [...]
Glo & Spa-rkle Aesthetics and Medspa Celebrates 700-Plus 5-Star Google Reviews, Cementing Rank as Best Laser Tattoo Removal Medspa in Lubbock, Texas.
21/10/2025
Glo & Spa-rkle Aesthetics and Medical Spa achieves a significant milestone, reinforcing its commitment to excellence in aesthetic and wellness services. Lubbock, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Glo & Spa- [...]
Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million
21/10/2025
CHICAGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has acquired an [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 42 - 2025
21/10/2025
Aggregated presentation by day and by market Statement of transactions in own shares from October 13th to October 17th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 42 - 2025
21/10/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 13 Octobre au 17 Octobre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year
21/10/2025
ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced its Burlington, MA sterile drug product facility has [...]
Raw Garden Acquires “California Love” to Grow Their Clean Cannabis Movement
21/10/2025
Acquisition strengthens Raw Garden’s mission to expand access to clean cannabis across California SANTA BARBARA, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Raw Garden, California’s leader in clean cannabis for over a [...]
Consortium consisting of Nordic Capital and Permira lowers the minimum acceptance condition to 66 2/3% in respect of the takeover offer to the shareholders of Bavarian Nordic
21/10/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Ultrack Systems Inc. (OTC: MJLB) Engages Empire Media Worx to Spearhead Major Rebranding and Market Expansion for Better Pets Division
21/10/2025
TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) (“Ultrack” or the “Company”), a diversified technology and asset management company, is pleased to announce that it has signed a Memorandum of [...]
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
21/10/2025
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“ [...]
CYIOS Corporation (OTC: CYIO) Announces Leadership Transition and Engages Artificial Intelligence (AI) and Software-as-a-Service (SaaS) advisors
21/10/2025
MELBOURNE, Australia and PALM BEACH, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CYIOS Corporation (OTC: CYIO) today announced that David Lewis has stepped down from his roles with CYIOS, and as part of this transition, he [...]
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
21/10/2025
- Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ® , the innovative alpha-radiation cancer therapy designed for potent and conformal tumor [...]
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
21/10/2025
MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who [...]
SS Innovations to Participate in Upcoming Investor Conferences
21/10/2025
FORT LAUDERDALE, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making [...]
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
21/10/2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for [...]
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
21/10/2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients [...]
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
21/10/2025
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE [...]

Pages